Compare CFFN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | NEO |
|---|---|---|
| Founded | 1893 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 1.0B |
| IPO Year | 2010 | 2008 |
| Metric | CFFN | NEO |
|---|---|---|
| Price | $7.61 | $8.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.25 | ★ $13.38 |
| AVG Volume (30 Days) | 855.9K | ★ 2.2M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $16,300,000.00 | N/A |
| Revenue This Year | $20.16 | $10.63 |
| Revenue Next Year | $6.62 | $9.73 |
| P/E Ratio | $23.53 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $5.51 | $4.72 |
| 52 Week High | $7.97 | $13.74 |
| Indicator | CFFN | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 46.83 |
| Support Level | $7.47 | $7.50 |
| Resistance Level | $7.85 | $8.84 |
| Average True Range (ATR) | 0.16 | 0.55 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 39.08 | 10.44 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.